Camurs gets FDA’s green light to kick off phase 3 testing of treatment of acromegaly and neuroendocrine tumors

Camurus will start with the Phase 3 study of once-monthly octreotide subcutaneous depot for treatment of acromegaly CAM2029.

The Swedish company got an Investigational New Drug (IND)  approval from the US Food and Drug Administration (FDA), to start the pivotal Phase 3 study of CAM2029 octreotide subcutaneous depot for the treatment of acromegaly.

Fredrik Tiberg, President & CEO of Camurus, said: “CAM2029 has the potential to become the first long-acting octreotide product that can be conveniently self-administered, thereby contributing to an improved quality of life for patients with this severe and chronic disorder.”